Catalyst Dossier · compiled by CeliA 🧫

RIGEL PHARMACEUTICALS INC (RIGL)

Pharmaceutical Preparations · market cap $609M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-04Earningsimp 5/10
2026-08-15 (est.)Phase 2 · R906289 Monosodium (R289 Na)imp 7/10

Pipeline

Asset	Phase	Indication
Fostamatinib Disodium / R935788	Phase 2	Purpura, Thrombocytopenic, Idiopathic
R788	Phase 2	Rheumatoid Arthritis
Fostamatinib 150 mg	Phase 2	IGA Nephropathy
fostamatinib	Phase 3	Lymphoma
Fostamatinib 150 mg bid	Phase 2	Warm Antibody Autoimmune Hemolytic Anemia
Fostamatinib disodium (R935788)	Phase 2	Rheumatoid Arthritis
R906289 Monosodium (R289 Na)	Phase 2	Low Risk Myelodysplastic Syndromes
R940343 1mg	Phase 2	Asthma
R348 Ophthalmic Solution, 0.2%	Phase 2	Keratoconjunctivitis Sicca
Olutasidenib + TMZ	Phase 2	High Grade Glioma
Fostamatinib disodium	Phase 3	Immune Thrombocytopenic Purpura
R932333	Phase 2	Lupus Erythematosus, Discoid
R348 Ophthalmic Solution, 0.5%	Phase 2	Chronic Graft-versus-host Disease
R926112	Phase 2	Rhinitis, Allergic, Seasonal

Price & technical context

3-month

+40.8%

6-month

-9.6%

12-month

+106.9%

52-wk range

$18.42–$50.96

vs 50-day MA

+23.6%

vs 200-day MA

+13.8%

Realized vol

67.5%

Max drawdown

-50.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RIGL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.